Rapid rise of serum testosterone following discontinuation of long term treatment of prostate carcinoma with an LHRH-agonist.
Kreis
W
W
Department of Medicine, North Shore University Hospital, Manhasset, N.Y.
Budman
D R
DR
Delli Bovi
P
P
Vinciguerra
V
V
D002064:Buserelin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D017273:Goserelin; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000097:blood / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013375:Substance Withdrawal Syndrome / Q000097:blood*; D013739:Testosterone / Q000097:blood*
D017273:Goserelin; D013739:Testosterone; D002064:Buserelin